{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:30:50Z","timestamp":1761863450436,"version":"3.37.3"},"reference-count":28,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,12]],"date-time":"2019-11-12T00:00:00Z","timestamp":1573516800000},"content-version":"vor","delay-in-days":1564,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"French Health Ministry"},{"DOI":"10.13039\/501100004099","name":"Ligue Nationale Contre le Cancer","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004099","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004339","name":"Sanofi-Aventis","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1093\/annonc\/mdv216","type":"journal-article","created":{"date-parts":[[2015,5,6]],"date-time":"2015-05-06T01:03:21Z","timestamp":1430874201000},"page":"1692-1697","source":"Crossref","is-referenced-by-count":12,"title":["UNICANCER-PEGASE 07 study: a randomized phase III trial evaluating postoperative docetaxel\u20135FU regimen after neoadjuvant dose-intense chemotherapy for treatment of inflammatory breast cancer"],"prefix":"10.1016","volume":"26","author":[{"given":"A.","family":"Gon\u00e7alves","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.-Y.","family":"Pierga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.-M.","family":"Ferrero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.-A.","family":"Mouret-Reynier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Bachelot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Delva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Fabbro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Lerebours","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.-P.","family":"Lotz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Linassier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Dohollou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.-C.","family":"Eymard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Leduc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Lemonnier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.-L.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.-M.","family":"Boher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Viens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Roch\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1093\/annonc\/mdv216_bb0010","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/annonc\/mdq345","article-title":"International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment","volume":"22","author":"Dawood","year":"2011","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1093\/annonc\/mdv216_bb0015","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1002\/cncr.22927","article-title":"Inflammatory breast cancer (IBC) and patterns of recurrence: understanding the biology of a unique disease","volume":"110","author":"Cristofanilli","year":"2007","journal-title":"Cancer"},{"issue":"1 Suppl","key":"10.1093\/annonc\/mdv216_bb0020","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1002\/cncr.2820741336","article-title":"Management of locally advanced carcinoma of the breast. II. Inflammatory carcinoma","volume":"74","author":"Perez","year":"1994","journal-title":"Cancer"},{"issue":"9","key":"10.1093\/annonc\/mdv216_bb0025","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1002\/cncr.25682","article-title":"Differences in survival among women with stage III inflammatory and noninflammatory locally advanced breast cancer appear early: a large population-based study","volume":"117","author":"Dawood","year":"2011","journal-title":"Cancer"},{"issue":"4","key":"10.1093\/annonc\/mdv216_bb0030","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1002\/1097-0142(19870815)60:4<897::AID-CNCR2820600430>3.0.CO;2-S","article-title":"Inflammatory breast cancer. Determination of prognostic factors by univariate and multivariate analysis","volume":"60","author":"Chevallier","year":"1987","journal-title":"Cancer"},{"issue":"4","key":"10.1093\/annonc\/mdv216_bb0035","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s002800050664","article-title":"Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M. D. Anderson Cancer Center","volume":"40","author":"Ueno","year":"1997","journal-title":"Cancer Chemother Pharmacol"},{"issue":"6","key":"10.1093\/annonc\/mdv216_bb0040","doi-asserted-by":"crossref","first-page":"415","DOI":"10.3816\/CBC.2004.n.004","article-title":"Paclitaxel improves the prognosis in estrogen receptor negative inflammatory breast cancer: the M. D. Anderson Cancer Center experience","volume":"4","author":"Cristofanilli","year":"2004","journal-title":"Clin Breast Cancer"},{"issue":"7","key":"10.1093\/annonc\/mdv216_bb0045","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1200\/JCO.1999.17.7.2006","article-title":"Outcomes of high-dose chemotherapy and autologous stem-cell transplantation in stage IIIB inflammatory breast cancer","volume":"17","author":"Adkins","year":"1999","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1093\/annonc\/mdv216_bb0050","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/sj.bmt.1701074","article-title":"High-dose chemotherapy and haematopoietic stem cell transplantation for inflammatory breast cancer: pathologic response and outcome","volume":"21","author":"Viens","year":"1998","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"10.1093\/annonc\/mdv216_bb0055","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/sj.bmt.1704458","article-title":"Multivariate analysis of survival in inflammatory breast cancer: impact of intensity of chemotherapy in multimodality treatment","volume":"33","author":"Bertucci","year":"2004","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"10.1093\/annonc\/mdv216_bb0060","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1200\/JCO.2004.10.147","article-title":"Prognostic indicators and survival in patients with stage IIIB inflammatory breast carcinoma after dose-intense chemotherapy","volume":"22","author":"Somlo","year":"2004","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1093\/annonc\/mdv216_bb0065","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/sj.bjc.6690714","article-title":"First-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer: toxicity and response (PEGASE 02 trial)","volume":"81","author":"Viens","year":"1999","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdv216_bb0070","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1200\/jco.2004.22.90140.848","volume":"22","author":"Palangie","year":"2004","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1093\/annonc\/mdv216_bb0075","doi-asserted-by":"crossref","first-page":"4165","DOI":"10.1200\/JCO.2003.12.005","article-title":"The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27","volume":"21","author":"Bear","year":"2003","journal-title":"J Clin Oncol"},{"issue":"9938","key":"10.1093\/annonc\/mdv216_bb0080","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet"},{"issue":"1","key":"10.1093\/annonc\/mdv216_bb0085","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2307\/2531910","article-title":"Sample sizes based on the log-rank statistic in complex clinical trials","volume":"44","author":"Lakatos","year":"1988","journal-title":"Biometrics"},{"issue":"2","key":"10.1093\/annonc\/mdv216_bb0090","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life table","volume":"34","author":"Cox","year":"1972","journal-title":"J R Stat Soc [B]"},{"issue":"3","key":"10.1093\/annonc\/mdv216_bb0095","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1093\/biomet\/80.3.557","article-title":"Checking the Cox model with cumulative sums of martingale-based residuals","volume":"80","author":"Lin","year":"1993","journal-title":"Biometrika"},{"issue":"424","key":"10.1093\/annonc\/mdv216_bb0100","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1080\/01621459.1993.10476416","article-title":"Cox regression with incomplete covariate measurements","volume":"88","author":"Lin","year":"1993","journal-title":"J Am Stat Assoc"},{"issue":"13","key":"10.1093\/annonc\/mdv216_bb0105","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1200\/JCO.2005.04.1665","article-title":"Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27","volume":"24","author":"Bear","year":"2006","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1093\/annonc\/mdv216_bb0110","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1093\/annonc\/mdt525","article-title":"Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes","volume":"25","author":"Masuda","year":"2014","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1093\/annonc\/mdv216_bb0115","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1200\/JCO.2007.10.8399","article-title":"Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer","volume":"26","author":"Piccart-Gebhart","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdv216_bb0120","doi-asserted-by":"crossref","first-page":"3686","DOI":"10.1200\/JCO.2005.10.517","article-title":"Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28","volume":"23","author":"Mamounas","year":"2005","journal-title":"J Clin Oncol"},{"issue":"36","key":"10.1093\/annonc\/mdv216_bb0125","doi-asserted-by":"crossref","first-page":"5664","DOI":"10.1200\/JCO.2006.07.3916","article-title":"Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial","volume":"24","author":"Roch\u00e9","year":"2006","journal-title":"J Clin Oncol"},{"issue":"9712","key":"10.1093\/annonc\/mdv216_bb0130","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/S0140-6736(09)61964-4","volume":"375","author":"Gianni","year":"2010","journal-title":"Lancet"},{"issue":"1","key":"10.1093\/annonc\/mdv216_bb0135","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(11)70336-9","article-title":"Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial","volume":"13","author":"Gianni","year":"2012","journal-title":"Lancet Oncol"},{"issue":"9816","key":"10.1093\/annonc\/mdv216_bb0140","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S0140-6736(11)61847-3","article-title":"Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial","volume":"379","author":"Baselga","year":"2012","journal-title":"Lancet"},{"issue":"4","key":"10.1093\/annonc\/mdv216_bb0145","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1470-2045(12)70049-9","article-title":"Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study","volume":"13","author":"Pierga","year":"2012","journal-title":"Lancet Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419318459?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419318459?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/26\/8\/1692\/16699737\/mdv216.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,8]],"date-time":"2024-06-08T20:44:52Z","timestamp":1717879492000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419318459"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8]]},"references-count":28,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["S0923753419318459"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdv216","relation":{},"ISSN":["0923-7534"],"issn-type":[{"type":"print","value":"0923-7534"}],"subject":[],"published":{"date-parts":[[2015,8]]}}}